TABLE 3.

Effect of study interventions on laboratory parameters

	Baseline Placebo	Baseline Cranberry	p	Acute Placebo	Acute Cranberry	p	4month Placebo	4month Cranberry	p	Delta Placebo 4month-Baseline	Delta Cranberry 4month-Baseline	p
hsCRP	0.1(0.1, 0.2)	0.1(0.0, 0.3)	0.70	0.1(0.1, 0.2)	0.1(0.0, 0.3)	0.40	0.1(0.1, 0.2)	0.1(0.0, 0.3)	0.77	5.8(−20.2, 47.9)	21.1(−6.2, 81.9)	0.21
VCAM	544.0(483.0, 666.0)	534.5(432.5, 623.0)	0.38	548.0(458.0, 654.0)	538.0(431.0, 583.0)	0.35	546.0(502.0, 726.0)	550.0(469.0, 664.0)	0.45	2.4(−1.2, 7.4)	2.5(−2.5, 9.8)	0.79
ICAM	193.5(156.5, 215.5)	189.0(159.0, 213.0)	0.85	173.0(155.0, 220.0)	172.0(156.0, 213.0)	0.83	191.0(172.0, 210.0)	199.0(174.0, 228.0)	0.33	1.0(−8.9, 6.8)	2.1(−1.4, 10.8)	0.35
II-6	1.1(0.9, 1.5)	1.2(0.6, 1.5)	0.49	1.1(0.9, 1.5)	1.2(0.6, 1.5)	0.42	1.2(0.9, 1.9)	1.4(1.0, 1.7)	0.72	0.0(−18.2, 60.0)	16.7(−6.7, 83.3)	0.29
TNF-alpha	1.1(0.7, 1.3)	1.3(0.6, 1.5)	0.53	1.1(0.8, 1.7)	1.1(0.8, 1.3)	0.78	1.0(0.7, 1.3)	1.1(0.8, 1.3)	0.39	0.0(−40.5, 12.8)	−5.4(−15.4, 13.3)	0.55
oxLDL	2.7(2.0, 4.3)	3.2(1.8, 16.7)	0.35	2.8(2.0, 4.8)	3.0(1.7, 16.6)	0.63	2.3(1.9, 3.4)	3.1 (1.8, 18.2)	0.16	−0.1 (−0.4, 0.1)	0(−0.2, 0.1)	0.21
Cholesterol	186.0(165.0, 210.0)	180.5(152.0, 213.0)	0.61	191.0(160.0, 207.0)	180.0(146.0, 204.0)	0.43	197.0(167.0, 217.0)	179.0(157.0, 220.0)	0.39	5.3(0.0, 9.5)	3.8(−0.9, 7.2)	0.44
HDL	51.0(38.0, 59.0)	45.5(35.0, 62.0)	0.90	50.0(37.0, 56.0)	45.0(36.0, 62.0)	0.91	52.0(44.0, 57.0)	48.0(36.0, 63.0)	0.54	4.7(−5.1, 15.6)	0.0(−6.7, 4.2)	0.12
TG	93.0(83.0, 138.0)	104.5(62.0, 143.0)	0.97	97.0(82.0, 144.0)	104.0(66.0, 142.0)	0.79	95.0(76.0, 132.0)	87.0(68.0, 166.0)	0.65	−9.0(−24.4, 14.5)	6.5(−12.6, 24.7)	0.09

hsCRP= high sensitivity C-reactive protein (mg/l), VCAM = vascular cell adhesion molecule, (ng/ml) ICAM = inter-cellular adhesion molecule, (ng/ml) IL-6 = Interleukin-6 (pg/ml), TNF = tumor necrosis factor (pg/ml), oxLDL = oxidized low density lipoprotein , HDL = high density lipoprotein (mg/dl), TG = triglyceride (mg/dl)